Predictors of Sustained Virological Response in Chronic Hepatitis C Patients Treated with Current Direct Acting Antiviral Drugs

A Study of Hepatocellular Carcinoma in Chronic Hepatitis C Patients Received Direct Acting Antiviral Drugs

Direct Acting Antivirals Impact on Biochemical, Immunological and Hematological Responses in HCV Infected Patients

Risk Assessment of Hepatitis C Virus Resistance to Ns3/4a Protease Inhibitors (Pis)

Effect of Direct Acting Anti-viral Agents on Insulin Resistance in Chronic HCV Patients

Molecular Characterization of NS5A Resistance Associated Substitutions after Failure of Sofosbuvir/Daclatasvir Combination Therapy in Chronic Hepatitis C genotype 4a Infected Egy

Study of Frequency of Hepatocellular Carcinoma Development after Direct Acting Antiviral Therapy in Hepatitis C Virus Patients

Comparative Study between Responders and Non Responders Among Patients Treated for Hepatitis C virus Infection

Association of multiple mutations in NS5A and NS5B genes and resistance to direct-acting antivirals in chronically infected Egyptian patients with Hepatitis C virus Genotype 4a

Recent trends in chronic hepatitis C virus treatment